Iovance Biotherapeutics, Inc. (IOVA) News Headlines

▮ More

Date

Headline

9/23/2021 7:47:29 AM Iovance Biotherapeutics Begins Clinical Supply Of TIL Cell Therapy Manufactured At Iovance Cell Therapy Center

6/29/2021 10:14:24 AM Iovance Biotherapeutics Down 4%; Releases Clinical Data For Its TIL Therapy LN-145

6/29/2021 6:34:47 AM Iovance Biotherapeutics Announces Clinical Data For LN-145 In Non-Small Cell Lung Cancer

5/20/2021 11:08:52 AM Stock Alert: Iovance Biotherapeutics Up 16%

5/18/2021 5:18:22 PM Iovance Biotherapeutics Shares Slip 10% On FDA's Feed Back On Lifileucel

12/14/2020 7:06:14 AM Iovance Biotherapeutics Appoints Jean-Marc Bellemin As CFO

11/8/2020 9:52:03 AM Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing

10/6/2020 10:07:55 AM Stock Alert: Iovance Biotherapeutics Down 16% On Delay In BLA Submission

10/6/2020 6:38:03 AM Pre-market Movers In Healthcare Sector: XTNT, BNTX, GLYC, ALNA, MGEN, IOVA, ARTL…

10/6/2020 2:39:29 AM GSK, AZN 1st To Use NVDA's Supercomputer, IOVA To Delay BLA Filing, YMAB Plunges, GLYC On Watch

10/5/2020 6:14:28 PM After Market Hours: Alteryx, GlycoMimetics, Spartan Energy Gain; Iovance, Y-mAbs Slip

5/13/2020 11:15:21 PM FDA Snubs BMY And BLUE, Stocks That Moved On ASCO Abstracts (ARVN, CTMX, MGNX)

3/25/2020 2:52:08 AM AMPE Suspends Recruitment In Study On Virus Risks, IMAC Rockets, SCPH On Watch

2/26/2020 3:08:08 AM Stock Alert: Iovance Biotherapeutics Inc. (IOVA) Shares Hit 52-Week High

2/25/2020 10:08:37 PM IOVA Abuzz, SUPN Study Flops, IMV Plunges Despite Positive Ovarian Cancer Data

1/15/2020 8:20:46 AM Iovance Completes Patient Dosing In Registration-Enabling Cohort 4 Of C-144-01 Melanoma Study With Lifileucel

1/12/2020 8:07:27 PM Iovance And Cellectis Enter Into Research Collaboration And Exclusive Worldwide License Deal

1/12/2020 8:05:00 PM Iovance Biotherapeutics Obtains License To Develop And Commercialize Novel IL-2 Analog

4/10/2018 8:45:12 AM B. Riley FBR Upgrades Iovance Biotherapeutics, Inc. (IOVA) To Buy From Neutral With $22 Price Target

Older Articles